Our Current Trials

Condition Trial Name Sponsor
High-risk HER2-positive Early-stage Breast Cancer(DESTINY-Breast11) A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan(T-DXd) Monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with High-risk HER2-positive Early-stage Breast Cancer(DESTINY-Breast11) AstraZeneca
B-Cell Malignancies A Phase I/II,Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies InnoCare Pharma Inc.
Advanced Hepatocellular Carcinoma A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination with Nivolumab as a Second-line Treatment in Subjects with Advanced Hepatocellular Carcinoma Kintor
First-line HER2-positive Breast Cancer (DESTINY-Breast09). A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in First-line HER2-positive Breast Cancer (DESTINY-Breast09). AstraZeneca
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Roche
Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Roche-Genetech
advanced solid tumors with genomic alterations or protein expression patterns predictive of response An Open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response Roche-Genetech
Newly diagnosed diffuse large B-cell lymphoma (DLBCL) Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL MorphoSys AG
Advanced/Metastatic Non-small Cell Lung Cancer Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer GSK
Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer G1 Therapeutics Inc